Chicago and Maywood, Ill. From the Division of Plastic and Reconstructive Surgery, the Department of Preventative Medicine, and the Lynn Sage Breast Center, Northwestern University, Feinberg School of Medicine, and Loyola University Chicago, Stritch School of Medicine.
Plast Reconstr Surg. 2012 Jan;129(1):28-41. doi: 10.1097/PRS.0b013e3182361fd6.
BACKGROUND: Human acellular dermal matrix has become an increasingly used adjunct to traditional submuscular tissue expander/implant breast reconstruction, but there is no strong consensus regarding complication outcomes. This study stratified outcomes based on a meta-analysis of complications. METHODS: A query of the MEDLINE database for articles on human acellular dermal matrix and submuscular tissue expander breast reconstruction yielded 901 citations. Two levels of screening identified 48 relevant studies. The DerSimonian and Laird random-effects model was used to perform the meta-analysis. Risk ratios and pooled complication rates were calculated for each outcome of interest. RESULTS: Nineteen studies reporting human acellular dermal matrix (n = 2037) and 35 reporting submuscular outcomes (n = 12,847) were used to estimate complication rates. Rates were generally higher in acellular dermis patients: total complications, 15.4 versus 14.0 percent; seroma, 4.8 versus 3.5 percent; infection, 5.3 versus 4.7 percent; and flap necrosis, 6.9 versus 4.9 percent. Six studies reporting both acellular dermis and submuscular outcomes were used to estimate relative risks. There was an increased risk of total complications (relative risk, 2.05; 95 percent CI, 1.55 to 2.70), seroma (relative risk, 2.73; 95 percent CI, 1.67 to 4.46), infection (relative risk, 2.47; 95 percent CI, 1.71 to 3.57), and reconstructive failure (relative risk, 2.80; 95 percent CI, 1.76 to 4.45) in acellular dermis patients. CONCLUSIONS: The meta-analysis suggests that the use of human acellular dermal matrix increases complication rates vis-à-vis submuscular expander/implant reconstruction. This must be weighed against its reported advantages in enhancing cosmesis and ameliorating contracture. CLINICAL QUESTION/LEVEL OF EVIDENCE: : Therapeutic, III.
背景:脱细胞真皮基质已成为传统胸肌下组织扩张器/植入物乳房再造的常用辅助手段,但对于并发症结果尚无明确共识。本研究基于并发症的荟萃分析对结果进行分层。
方法:对 MEDLINE 数据库中有关脱细胞真皮基质和胸肌下组织扩张器乳房再造的文章进行查询,共获得 901 条引文。通过两级筛选确定了 48 项相关研究。采用 DerSimonian 和 Laird 随机效应模型进行荟萃分析。计算了每个感兴趣结局的风险比和汇总并发症发生率。
结果:19 项报告脱细胞真皮基质(n = 2037)和 35 项报告胸肌下结果(n = 12847)的研究用于估计并发症发生率。脱细胞真皮基质患者的发生率普遍较高:总并发症发生率为 15.4%比 14.0%;血清肿发生率为 4.8%比 3.5%;感染发生率为 5.3%比 4.7%;皮瓣坏死发生率为 6.9%比 4.9%。6 项同时报告脱细胞真皮基质和胸肌下结果的研究用于估计相对风险。总并发症的风险增加(相对风险,2.05;95%置信区间,1.55 至 2.70)、血清肿(相对风险,2.73;95%置信区间,1.67 至 4.46)、感染(相对风险,2.47;95%置信区间,1.71 至 3.57)和重建失败(相对风险,2.80;95%置信区间,1.76 至 4.45)。
结论:荟萃分析表明,与胸肌下扩张器/植入物重建相比,使用脱细胞真皮基质会增加并发症发生率。这必须与它在改善美容效果和减轻挛缩方面的报道优势相权衡。
临床问题/证据水平:治疗性,III 级。
Plast Reconstr Surg. 2012-1
Plast Reconstr Surg. 2012-12
Plast Reconstr Surg. 2012-5
Plast Reconstr Surg Glob Open. 2025-7-10
Plast Reconstr Surg Glob Open. 2025-6-6
J Plast Reconstr Surg. 2023-11-28
Cancers (Basel). 2024-9-20
Plast Reconstr Surg Glob Open. 2024-8-16